Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China

GLP-1 RA or GIP/GLP-1RA are not cost-effective for obesity treatment in China currently. Nevertheless, semaglutide exhibits relatively favourable economic potential across multiple subgroups.